2019
A novel anti-melanoma SRC-family kinase inhibitor
Halaban R, Bacchiocchi A, Straub R, Cao J, Sznol M, Narayan D, Allam A, Krauthammer M, Mansour TS. A novel anti-melanoma SRC-family kinase inhibitor. Oncotarget 2019, 10: 2237-2251. PMID: 31040916, PMCID: PMC6481345, DOI: 10.18632/oncotarget.26787.Peer-Reviewed Original ResearchSrc family kinase inhibitorMAPK inhibitorTranscription factor MITFPatient-derived melanoma cellsPI3K activityKinase inhibitorsSynergistic growth inhibitionGrowth arrestMelanoma cell linesK activityProteolytic degradationCell linesERBB2 inhibitionOncogene expressionMelanoma therapyTumor growthDrug resistanceMelanoma cellsGrowth inhibitionAlternative targetsActivity leadInhibitorsPP2ASHP2Inhibition
2002
COMMENTARY Pigmentation in Melanomas: Changes Manifesting Underlying Oncogenic and Metabolic Activities
Halaban R. COMMENTARY Pigmentation in Melanomas: Changes Manifesting Underlying Oncogenic and Metabolic Activities. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 2002, 13: 3-8. PMID: 12201672, DOI: 10.3727/096504002108747908.Peer-Reviewed Original ResearchConceptsMelanocyte-specific gene expressionTranscription factor MITFDownregulation of tyrosinaseEpigenetic levelV-ATPaseRate-limiting enzymeTranscriptional activityGene expressionAcidified microenvironmentsAmelanotic melanoma cellsC-MycActivity of tyrosinaseEnhanced glycolysisMelanin synthesisExtracellular acidificationMelanoma tumorsTYR activityMelanoma cellsMetabolic activityPigmentationAnaerobic conditionsTyrosinase activityMetastatic melanocytic lesionsMetabolic changesTyrosinase